ProCE Banner Activity

ECHELON-3: Phase III, Placebo-Controlled Trial of Brentuximab Vedotin in Combination With Lenalidomide and Rituximab in R/R DLBCL

Conference Coverage
Slideset

Interim analysis of results from the phase III ECHELON-3 study showed that the combination of brentuximab vedotin with lenalidomide and rituximab significantly improved overall survival, progression-free survival, and overall response rate compared with placebo plus lenalidomide and rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma. 

Released: June 06, 2024

Expiration: June 05, 2025

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from GSK, Lilly, Novartis Pharmaceuticals Corporation, and Sanofi.

GSK

Lilly

Novartis Pharmaceuticals Corporation

Sanofi